Resonance Specialties has initiated a postal ballot process to seek shareholder approval for the acquisition of a manufacturing facility from its related party, Kaygee Laboratories Private Limited (KLPL). The proposed transaction involves the purchase of KLPL’s manufacturing unit located in Mandideep, Madhya Pradesh, for a lump-sum consideration of ₹29.98 crore on a slump sale basis.

The acquisition includes leasehold land measuring approximately 22,304 square meters, industrial buildings of about 5,227 square meters, along with associated plant machinery, licenses, permits, and employees. Resonance currently sources chemical intermediates and certain Active Pharmaceutical Ingredients (APIs) from this facility under a job work agreement. The company states that acquiring the unit will enable vertical integration, particularly in the field of pyridine, collidines, and their derivatives, while eliminating outsourcing costs.

Transaction Details

The deal is classified as a material related party transaction under SEBI Listing Regulations. The consideration was determined based on a valuation report dated July 24, 2026, issued by S R Valuers, an IBBI-registered valuer. Funding for the acquisition will be sourced partly from internal accruals and partly through borrowings.

Related Party Dynamics

KLPL belongs to the same promoter group as Resonance Specialties. Directors Mr. Prashant Godha and Mr. Charchit Jain serve as directors in both entities. Additionally, KLPL indirectly holds a stake in Resonance through its 14.35% equity holding in Makers Laboratories Limited, which in turn holds 45.48% of Resonance. Another promoter-group entity, Kaygee Investments Private Limited, holds an 8.77% stake in the listed company.

The Audit Committee and Board of Directors have approved the transaction, citing it as arm’s length and in the ordinary course of business. The company notes that the acquisition will reduce the volume of future related party transactions by bringing the manufacturing capability in-house.

What the Numbers Show

The proposed outlay of ₹29.98 crore represents a significant capital commitment relative to the company’s recent scale. The transaction value accounts for 33.22% of Resonance Specialties’ annual turnover for FY25-26. In contrast, the consideration represents 102.25% of KLPL’s total income for FY24-25, which stood at ₹29.32 crore. This divergence highlights that the valuation is driven by the strategic utility and asset base of the manufacturing facility rather than the seller’s standalone revenue generation capacity.

Voting Process

Shareholders as on the cut-off date of August 14, 2026, are eligible to vote. The remote e-voting facility will be available from 9:00 am on August 20, 2026, to 5:00 pm on September 18, 2026, via the National Securities Depository Limited (NSDL) platform. The results will be declared within two working days of the voting conclusion.

Resonance Specialties shareholders approved a final dividend of ₹1 per share and authorized related party transactions worth up to ₹40 crore during its 37th Annual General Meeting held on August 4, 2026. While the dividend and auditor re-appointment resolutions passed with near-unanimous support, the related party transaction resolution encountered measurable dissent from public investors, marking a divergence in shareholder sentiment.

The virtual meeting, presided over by Chairman Raj Kamal Prasad Verma, saw all six proposed resolutions passed. The Board of Directors proposed the dividend at 10% on the face value of ₹10 per equity share. Voting was conducted electronically between July 31, 2026, and August 3, 2026, with July 28, 2026, as the cut-off date. M/s Alok Khairwar & Associates served as the scrutinizer under Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Voting Breakdown by Resolution

Promoter group holdings of 6,262,201 shares voted in favor of all resolutions except the related party transaction, where they abstained. Public institutional holders did not vote on any resolution. The key differentiator was the "Public-Others" category, which held 5,106,148 shares but polled only 16,170 votes (0.3167% participation).

Governance and Compliance

The meeting adhered to strict regulatory standards. Representatives from Statutory Auditors, Secretarial Auditors, and the Scrutinizer were present via video conference. Chairman Raj Kamal Prasad Verma confirmed quorum presence throughout. He noted no qualifications or adverse remarks in the Independent Auditors Report or Secretarial Audit Report for the period ended March 31, 2026.

The Whole-time Director addressed member queries before the e-voting module remained open for an additional 15 minutes. Results were declared following the scrutinizer’s report and posted on the company’s website and registered office in Mumbai.

What the Numbers Show

The stark contrast in voting patterns reveals specific shareholder concerns. While governance items (auditors, director re-appointment) and capital return (dividend) enjoyed universal support, the related party transaction cap of ₹40 crore with Kaygee Laboratories Private Limited faced 745 votes against from the public-investor segment. This 4.6% opposition rate is significant given the low overall participation (0.31%) of retail investors. It suggests that while promoters are fully aligned with management, a subset of public shareholders remains cautious about the scale or terms of ongoing commercial ties with Kaygee Laboratories, despite the annual oversight mechanism.